Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘A Game Changer:’ Cures 2.0 Would Provide $11bn In ‘Subscription’ Contracts For New Antibiotics

Executive Summary

The PASTEUR Act would delink some of an antibiotic’s revenue from prescription sales, with the goal of revitalizing the antibiotic pipeline with additional private investment while encouraging good public health stewardship of critically needed medicines.

You may also be interested in...



Voluntary Limits On Antibacterial Discharges Increase As Fear Of Resistance Grows

Pharmaceutical companies are ratcheting up voluntary efforts to control discharges of antimicrobials from their plants and those of their active pharmaceutical ingredient suppliers so they won’t contribute to antimicrobial resistance. But will it be enough to fend off regulation in countries like India?

Cures 2.0 Leaders Sees Biden ‘Advanced Research’ Project As Ticket To Bill’s Success

Reps. Diana DeGette and Fred Upton are looking to President Biden and his new plan for a translation health research group at NIH to get their next itineration of 21st Century Cures  across the finish line. A discussion draft is expected in early June.

‘World’s First’ Antibiotic Incentive Scheme Kicks Off In UK

Pharmaceutical companies are being invited to join a pioneering UK “subscription-style” scheme intended to incentivize the development of innovative antibiotics for the most serious diseases. 

Related Content

Topics

UsernamePublicRestriction

Register

PS145273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel